MARKET OVERVIEW

Chronic hand eczema (CHE) is a painful and debilitating form of eczema localized to the hands that can seriously impact a patient’s quality of life. No prescription therapies are yet available for CHE; rather, current treatment is focused on topical or systemic corticosteroids, oral immunosuppressants, or, in some cases, off-label Dupixent. However, the FDA recently granted fast-track status to two emerging JAK inhibitors, one topical and one oral, raising physicians’ hopes for new treatments for CHE. Physicians treating CHE are enthusiastic about having more topical treatments and report a high level of unmet need for safe, effective treatments, with a slight preference for topical therapy.

QUESTIONS ANSWERED

  • How many CHE patients are diagnosed, and how many receive patch testing? What percentage have underlying atopy?
  • What is the typical treatment algorithm for a CHE patient? What percentage of patients receive a given drug as first-, second-, or third-line treatment?
  • How is Dupixent used in the current CHE market?
  • How likely are physicians to prescribe an emerging CHE therapy to their mild, moderate, and severe patients?

PRODUCT DESCRIPTION

Executive Insights provides indication-specific market intelligence with world-class epidemiology, keen insight into current treatment paradigms, biotherapeutic pipelines, key clinical unmet needs, and competitive landscapes, supported by primary and secondary research. This solution provides succinct insights to any biopharma function or business professional looking to quickly grasp a new indication of interest.

Table of contents

  • Atopic Dermatitis/Atopic Eczema - Chronic Hand Eczema - Executive Insights - Executive Insights (US)
    • Chronic Hand Eczema-Executive-Insights

Author(s): Kristine Mackin, Ph.D.

Kristine Mackin, Ph.D., is a principal analyst on the Immune and Inflammatory Disorders team at DRG, part of Clarivate. Her expertise includes emerging microbiome-based therapies, psoriatic arthritis, chronic obstructive pulmonary disease, and asthma. Prior to joining DRG, Dr. Mackin was involved with a new company pitch focusing on the infant microbiome, now realized as Commense, during an internship at Puretech Ventures in Boston. She holds a doctorate in biochemistry from Brandeis University, where she studied the evolution of bacteriorhodopsin and the relationship between type I and type II rhodopsins.